AUGMENT INJECTABLE CLINICAL TRIAL OVERVIEW
Patient enrollment has begun for the clinical trialBioMimetic Therapeutics, Inc. is now recruiting candidates for the Augment® Injectable Bone Graft research study, a pivotal clinical study enrolling patients diagnosed with degenerative joint disease affecting the hindfoot. The purpose of this study is to evaluate the safety and efficacy of Augment Injectable Bone Graft as compared to the current standard, autograft, when implanted into the joint space in hindfoot fusions. If you have been diagnosed by your doctor with a degenerative joint disease requiring joint fusion in the hindfoot due to a congenital deformity, osteoarthritis, rheumatoid arthritis, post-traumatic arthritis or ankylosing spondylitis, you may qualify for this study. This randomized, controlled study will enroll approximately 200 volunteers. Up to 25 orthopedic clinical centers in the United States will participate in the clinical study, in addition to several sites in Canada. Patient screening has begun to determine eligibility for participation in the research behind a potentially promising treatment available as an alternative to autograft. All entry criteria must be met prior to clinical study enrollment. Foot Fact: Feet cushion up to one million pounds of pressure in one hour of strenuous exercise. If you are interested in learning more about the Augment Injectable Bone Graft Hindfoot Fusion Study, or would like information regarding clinical trial site locations in your area click here to contact us. |
